PT3634377T - Formulação farmacêutica - Google Patents

Formulação farmacêutica

Info

Publication number
PT3634377T
PT3634377T PT187296835T PT18729683T PT3634377T PT 3634377 T PT3634377 T PT 3634377T PT 187296835 T PT187296835 T PT 187296835T PT 18729683 T PT18729683 T PT 18729683T PT 3634377 T PT3634377 T PT 3634377T
Authority
PT
Portugal
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
PT187296835T
Other languages
English (en)
Original Assignee
Klaria Pharma Holding Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaria Pharma Holding Ab filed Critical Klaria Pharma Holding Ab
Publication of PT3634377T publication Critical patent/PT3634377T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT187296835T 2017-06-08 2018-06-08 Formulação farmacêutica PT3634377T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709141.4A GB201709141D0 (en) 2017-06-08 2017-06-08 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
PT3634377T true PT3634377T (pt) 2021-10-18

Family

ID=59358417

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187296835T PT3634377T (pt) 2017-06-08 2018-06-08 Formulação farmacêutica

Country Status (19)

Country Link
US (3) US11219600B2 (pt)
EP (2) EP3932399A1 (pt)
CN (1) CN110831575A (pt)
AU (1) AU2018279192A1 (pt)
BR (1) BR112019025552A2 (pt)
CA (1) CA3056992A1 (pt)
DK (1) DK3634377T3 (pt)
ES (1) ES2881710T3 (pt)
GB (1) GB201709141D0 (pt)
HR (1) HRP20211323T1 (pt)
HU (1) HUE055884T2 (pt)
IL (1) IL271226A (pt)
MX (1) MX2019012435A (pt)
PL (1) PL3634377T3 (pt)
PT (1) PT3634377T (pt)
RU (1) RU2019139286A (pt)
SI (1) SI3634377T1 (pt)
WO (1) WO2018224674A1 (pt)
ZA (1) ZA201906318B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381921A (zh) 2016-11-15 2019-10-25 卡里亚制药控股有限公司 药物制剂
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201911715D0 (en) * 2019-08-15 2019-10-02 Klaria Pharma Holding Ab Film formulation comprising carriers
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
EP4100012A4 (en) * 2020-02-05 2024-02-07 Summit Biosciences Inc. MEDICINAL PRODUCTS INTENDED TO BE ADMINISTERED BY INTRANASAL ROUTE AND ASSOCIATED USES
DE102021105268A1 (de) 2021-03-04 2022-09-08 Lts Lohmann Therapie-Systeme Ag. Oraler Dünnfilm
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
US20240009184A1 (en) * 2022-03-11 2024-01-11 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933462A (en) 1958-12-17 1963-08-08 Simone Marie Antoinette Radouc Improvements in or relating to the treatment of meat
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
AU3693397A (en) 1996-07-10 1998-02-02 Novartis Consumer Health S.A. Oral pharmaceutical combinations of antihistaminic compounds and terpenoids
WO1998002182A1 (en) 1996-07-12 1998-01-22 Novartis Consumer Health S.A. Oral pharmaceutical combinations of nsaids with terpenoids
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
KR100452972B1 (ko) 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20040247649A1 (en) 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
AU2003240824B9 (en) 2002-05-31 2008-09-25 University Of Mississippi Transmucosal delivery of cannabinoids
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB0217382D0 (en) 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US9561182B2 (en) 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
RU2342953C2 (ru) 2003-02-24 2009-01-10 Фармасьютикал Продакшенз, Инк. Трансмукозная система доставки лекарственных средств
US20070059346A1 (en) 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
KR20050048056A (ko) 2003-11-18 2005-05-24 (주)케이비피 경구용 소모 필름 조성물
US20080254108A1 (en) 2004-08-23 2008-10-16 Mark Rosenberg Formulations and Methods for Modulating Satiety
MX2007006233A (es) 2004-11-24 2007-11-23 Medpointe Healthcare Inc Composiciones que comprenden azelastina y metodos de uso de la misma.
US20060217308A1 (en) 2005-03-10 2006-09-28 Pascale Cossart Compositions for the treatment of tumor pathologies, comprising internalin B (ln1B) of Listeria monocytogene protein or a fragment thereof
ES2379190T3 (es) 2005-03-15 2012-04-23 Animal Ethics Pty Ltd Composición analgésica tópica
WO2007028247A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
GB2423711B (en) 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CN101081218A (zh) 2006-06-02 2007-12-05 范敏华 一种口腔速崩膜及其制备方法
WO2007143674A2 (en) 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
KR100855566B1 (ko) 2006-09-12 2008-09-03 (주) 아모젠 경구용 소모성 필름
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
AU2007333105A1 (en) 2006-12-11 2008-06-19 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
AU2008210329B2 (en) 2007-01-31 2013-11-28 Rutgers, The State University Of New Jersey Controlled release of actives in skin
WO2008098195A2 (en) 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
US20090246273A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
WO2009126132A1 (en) 2008-03-31 2009-10-15 Mark Rosenberg Formulations and methods for modulating satiety
NZ591261A (en) 2008-09-12 2012-12-21 Critical Pharmaceuticals Ltd Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
US8900634B2 (en) 2008-11-03 2014-12-02 Nal Pharmaceuticals, Ltd. Diethylstilbestrol dosage form and methods of treatment using thereof
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
CN101574330A (zh) 2009-06-12 2009-11-11 上海现代药物制剂工程研究中心有限公司 苯甲酸利扎曲普坦膜剂
KR101074271B1 (ko) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
PL3254676T3 (pl) 2009-10-30 2019-06-28 Ix Biopharma Ltd Szybko rozpuszczająca się stała postać dawkowana
KR101077468B1 (ko) 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
KR101303479B1 (ko) 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제
JP2014521641A (ja) 2011-07-29 2014-08-28 ケムファーム， インコーポレイテッド ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス
WO2013052770A1 (en) 2011-10-05 2013-04-11 Sanders Jennifer L Methods and compositions for treating foot or hand pain
US20140242177A1 (en) 2011-10-21 2014-08-28 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
WO2013171146A1 (en) 2012-05-15 2013-11-21 Lts Lohmann Therapie-Systeme Ag Oral film containing enteric release opiate resinate
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
CN102871984B (zh) 2012-11-05 2015-11-11 天津市聚星康华医药科技有限公司 一种盐酸去氧肾上腺素口腔速溶膜及其制备方法
CN102961365B (zh) 2012-12-17 2016-01-20 天津市聚星康华医药科技有限公司 硫酸特布他林口腔速溶膜及其制备方法
WO2014137189A1 (ko) 2013-03-07 2014-09-12 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법
WO2014160404A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Improved oral drug devices and drug formulations
CN105283170B (zh) 2013-06-17 2019-10-18 弗里蒙特集团有限公司 包含肾上腺素和柠檬酸的可注射的药物组合物
DE202013105715U1 (de) 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2015074663A1 (en) 2013-11-19 2015-05-28 Rigshospitalet Injectable pharmaceutical compositions comprising iloprost
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9956190B2 (en) 2014-04-15 2018-05-01 Vizuri Health Sciences Llc Topical compositions for pain relief, manufacture and use
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
CA2952622A1 (en) 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
US10307397B2 (en) 2014-07-28 2019-06-04 Concept Matrix Solutions Oral dissolvable film that includes plant extract
ES2705610T3 (es) * 2014-07-31 2019-03-26 Pharmathen Sa Composición de película orodispersable que comprende enalapril para el tratamiento de la hipertensión en una población pediátrica
US10383950B2 (en) 2014-08-14 2019-08-20 Helmholtz-Zentrum Fur Infektionsforschung Gmbh (De/De) Methods and compositions of carrier systems for the purpose of intracellular drug targeting
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
US10335398B2 (en) 2015-04-08 2019-07-02 Maxinase Life Sciences Limited Bioadhesive compositions for intranasal administration of granisetron
US10064816B2 (en) 2015-06-11 2018-09-04 ReJoy Treatment of sexual dysfunction
CA2987909C (en) 2015-06-27 2022-04-26 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CA2994331C (en) 2015-07-31 2023-10-03 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
US20170079907A1 (en) 2015-09-18 2017-03-23 Insys Development Company, Inc. Sublingual Epinephrine Spray
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US9833461B2 (en) 2015-10-23 2017-12-05 Ctt Pharma Inc. Therapeutic compositions comprising cannabidiol and corticosteroids
GB2551598B (en) 2016-01-07 2022-03-09 Viramal Ltd Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
WO2017132410A1 (en) 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
JPWO2017135195A1 (ja) 2016-02-03 2018-11-22 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤
WO2017180707A1 (en) 2016-04-12 2017-10-19 Schaneville Scott Ingestible films having substances from hemp or cannabis
US20180104195A1 (en) 2016-05-05 2018-04-19 Monosol Rx, Llc Enhanced delivery epinephrine compositions
US20180125977A1 (en) 2016-05-05 2018-05-10 Monosol Rx, Llc Enhanced delivery epinephrine compositions
EP3452024A1 (en) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN109310646A (zh) 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US20190350881A1 (en) 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
CN110381921A (zh) 2016-11-15 2019-10-25 卡里亚制药控股有限公司 药物制剂
CN107080745A (zh) 2017-04-14 2017-08-22 宁夏医科大学 一种载叶黄素白蛋白纳米粒的口腔速溶膜及其制备方法
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201807942D0 (en) 2018-05-16 2018-06-27 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201911715D0 (en) 2019-08-15 2019-10-02 Klaria Pharma Holding Ab Film formulation comprising carriers
GB201912505D0 (en) 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2021090309A1 (en) 2019-11-04 2021-05-14 Maabarot Products Ltd. Orally administrable films comprising poorly water soluble active ingredients and preparation thereof

Also Published As

Publication number Publication date
US11219600B2 (en) 2022-01-11
GB201709141D0 (en) 2017-07-26
AU2018279192A1 (en) 2019-10-17
ZA201906318B (en) 2022-05-25
RU2019139286A (ru) 2021-07-09
EP3634377A1 (en) 2020-04-15
SI3634377T1 (sl) 2021-11-30
EP3932399A1 (en) 2022-01-05
CN110831575A (zh) 2020-02-21
US11904049B2 (en) 2024-02-20
EP3634377B1 (en) 2021-07-21
HUE055884T2 (hu) 2021-12-28
BR112019025552A2 (pt) 2020-06-23
US20240165022A1 (en) 2024-05-23
RU2019139286A3 (pt) 2022-03-03
US20200246253A1 (en) 2020-08-06
WO2018224674A1 (en) 2018-12-13
HRP20211323T1 (hr) 2021-11-26
MX2019012435A (es) 2020-01-13
DK3634377T3 (da) 2021-08-30
ES2881710T3 (es) 2021-11-30
PL3634377T3 (pl) 2021-12-20
CA3056992A1 (en) 2018-12-13
IL271226A (en) 2020-01-30
WO2018224674A9 (en) 2019-03-21
US20220160618A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
GB201807942D0 (en) Pharmaceutical formulation
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271226A (en) medical preparation
ZA201903101B (en) Pharmaceutical formulations
IL271759A (en) Pharmaceutical preparations that include anthraxtinib
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
HK1245653A1 (zh) 藥物製劑
IL266537A (en) pharmaceutical preparation
ZA202102871B (en) Pharmaceutical formulation
IL253177B (en) Pharmacy preparation
IL269239A (en) A pharmaceutical combination containing fonsimod
IL278927A (en) pharmaceutical preparation
ZA201807851B (en) Pharmaceutical formulation
LT3601277T (lt) Farmacinė vaisto forma
EP3383371C0 (en) PHARMACEUTICAL FORMULATION
GB201506755D0 (en) Novel pharmaceutical formulation
IL275144A (en) Pharmacy preparation
GB201511246D0 (en) Pharmaceutical formulation
IL271908A (en) Over-compressed pharmaceutical preparations
GB201719873D0 (en) Pharmaceutical formulation
GB201604545D0 (en) Novel pharmaceutical formulation
GB201610440D0 (en) Pharmaceutical formulations